- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
- Interventions
- Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
- Diagnostic Test
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 42
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Transplant Failure and Rejection
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- Paul Kim
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson, Adenosine, N-13 ammonia
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Coronary Artery Disease
- Interventions
- Half-dose isotope for NuclearStressTest
- Other
- Lead sponsor
- S.M.Chang, MD
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sickle Cell Anemia
- Interventions
- Regadenoson, Placebo
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 10 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 12
- States / cities
- Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Coronary Artery Disease
- Interventions
- ASSUAGE Protocol
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Coronary Artery Disease
- Interventions
- SPECT imaging
- Radiation
- Lead sponsor
- Prem Soman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Coronary Artery Disease, Myocardial Perfusion Abnormalities
- Interventions
- Regadenoson; Optison
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Omaha, Nebraska
- Conditions
- Coronary Artery Disease, CAD
- Interventions
- regadenoson, Optimark®, Myocardial perfusion MRI
- Drug · Device
- Lead sponsor
- Daniel S. Berman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cardiology, Radiology, Stenoses
- Interventions
- CT-FFR and CTP
- Device
- Lead sponsor
- Lancaster General Hospital
- Other
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson, Adenosine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Coronary Artery Disease, Myocardial Ischemia
- Interventions
- Regadenoson, Symptom-limited exercise
- Drug · Other
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Coronary Artery Disease
- Interventions
- PET-MPI Protocol, CT-MPI, Coronary CT angiography (CCTA) for CT-FFR calculation, Regadenoson
- Diagnostic Test · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- PET MPI, SPECT MPI, Pharmacological stress agents
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson, Adenosine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Coronary Artery Disease, Coronary Microvascular Disease
- Interventions
- Myocardial Perfusion Cardiac MRI., Contrast, Pharmacologic Stress Agent
- Device · Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
- Interventions
- Aminophylline, Placebo
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
- Interventions
- Regadenoson, Gadolinium, Cardiac MRI
- Drug · Procedure
- Lead sponsor
- Paul Kim
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Coronary Artery Disease, Myocardial Perfusion Abnormalities
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Omaha, Nebraska
- Conditions
- Sickle Cell Disease
- Interventions
- [13N]NH3, Lexiscan, Positron emission tomography
- Drug · Diagnostic Test
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Veterans Referred to the St. Louis VAMC Stress Tes
- Interventions
- Regadenoson myocardial perfusion imaging stress test, Arm exercise electrocardiographic stress test, Treadmill electrocardiographic stress test, Coronary artery calcium score and cardiac computed tomographic angiography
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension
- Interventions
- regadenoson
- Drug
- Lead sponsor
- Marvin W. Kronenberg, M.D.
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Coronary Artery Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- Timothy M. Bateman
- Other
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri